Etropal ADXBUL:ETR 50 EBITDA Margin % is 6.82% as of Dec. 2025, which is 32% below its 10-year median of 10.04. GuruFocus rates XBUL:ETR with a GF Score™ of 50/100 and a GF Value™ of €8.55 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 816 Medical Devices & Instruments companies, Etropal AD ranks worse than 50.86% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Etropal AD's EBITDA for the
six
months ended in Dec. 2025 was €0.70 Mil. Etropal AD's Revenue for the
six
months ended in Dec. 2025 was €10.25 Mil. Therefore, Etropal AD's EBITDA margin for the quarter that ended in Dec. 2025 was 6.82%.
Etropal AD (XBUL:ETR) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Etropal AD EBITDA Margin % Related Terms
Etropal AD EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Etropal AD's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XBUL:ETR vs ISRG, BDX, MDLN: EBITDA Margin % Comparison
For the Medical Instruments & Supplies subindustry, Etropal AD's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Etropal AD EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Etropal AD's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Etropal AD's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Etropal AD (XBUL:ETR) has a EBITDA Margin % of 6.82% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Etropal AD and its competitors. This is 32% below median its historical median of 10.04. According to the industry distribution chart, Etropal AD ranks #415 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 50.9%.
Is Etropal AD's EBITDA Margin % too high?
Etropal AD's current EBITDA Margin % of 6.82% is 32% below median its 10-year median of 10.04. The Medical Devices & Instruments industry median EBITDA Margin % is 7.46. Etropal AD's value of 6.82% is 8.5% below this industry median. Based on the distribution chart, Etropal AD ranks #415 out of 816 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Etropal AD has a GF Score™ of 50/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Etropal AD's EBITDA Margin % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Etropal AD ranks #415 out of 816 companies for EBITDA Margin %. This places Etropal AD in the lower half of its industry. The industry median EBITDA Margin % is 7.46. Etropal AD's value of 6.82% is 8.5% below this benchmark. While the company's 10-year median is 10.04 vs. the industry median of 7.46, Etropal AD has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.46, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Etropal AD's current EBITDA Margin % of 6.82% is 8.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Etropal AD and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Etropal AD's current EBITDA Margin % is 6.82%, which is 32% below median its own 10-year median of 10.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Etropal AD stock overvalued right now?
Based on GuruFocus' analysis, Etropal AD (XBUL:ETR) is currently considered Significantly Undervalued. The stock's GF Value™ is €8.55, compared to a current price of €2.52 — trading 70.5% below its estimated fair value. The current EBITDA Margin % is 6.82%, which is 32% below median its 10-year median of 10.04 and 8.5% below the Medical Devices & Instruments industry median of 7.46. Etropal AD's overall GF Score™ is 50/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Etropal AD (XBUL:ETR), the current EBITDA Margin % is 6.82% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Etropal AD (XBUL:ETR) Overvalued in 2026?
Based on GuruFocus' analysis, Etropal AD stock appears to be undervalued.
The current stock price of €2.52 is trading 70.5% below its estimated GF Value™ of €8.55.
GuruFocus considers Etropal AD to be Significantly Undervalued.
Key valuation signals for XBUL:ETR:
EBITDA Margin %: 6.82% (32% below median its 10-year median of 10.04)
GF Value™: €8.55 vs. price of €2.52 (70.5% below fair value)
Industry Position: 8.5% below the Medical Devices & Instruments median (#415 of 816)
No single metric tells the full story. See the XBUL:ETR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Etropal AD is engaged in the business of manufacturing medical accessories. The product portfolio includes fistula needles, blood taking sets, transfusion and infusion sets, catheters and tubes, urine collecting bags, colostomy bags, among others. The company also produces hip - joint endoprosthesis and instruments of implantation.
50GF Score
Get the complete analysis for XBUL:ETR
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XBUL:ETR has been successfully added to your 
